Indication
Non-Small Cell Lung Cancer
The Non-Small Cell Lung Cancer pipeline: 609 tracked drugs, 58 approved for this indication.
58 approved / phase 4101 Phase 314 Phase 2/384 Phase 2142 Phase 1/2157 Phase 153 preclinical / unstaged
Compare the share prices of listed companies in Non-Small Cell Lung Cancer →
Total attributable cost
$12.5B
$70,896/patient
Drug spend
$4.8B
$27,138/patient
38% of total cost is drugs
All stages, newly diagnosed (2026 incidence estimate) · US